The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Hims & Hers shares plunged 14% to approximately $25 following first-quarter results that revealed a net loss of $92.1 million. The company reported revenue of $608.1 million, missing the Bloomberg consensus estimate of $617.5 million, and slashed its full-year adjusted EBITDA guidance to a range of $275 million to $350 million. Results were heavily impacted by $33.5 million in restructuring charges stemming from a strategic pivot from copycat GLP-1s to branded obesity medications.
Sign in to access this content
Sign InThe sell-off was further fueled by a contraction in gross margin, which fell to 65% from 73% year-over-year, missing the 71.7% analyst estimate per market data. This operational strain mirrors broader difficulties in the telehealth sector, where peers like Teladoc Health have declined over 30% year-to-date per market data. Analysts suggest the pivot to branded drugs is a necessary but costly move to secure long-term market share against intensifying competition.
Investors are currently monitoring technical support near the $24.50 level, with the stock priced at $25.00 (close May 12, 2026). Looking ahead, market participants are focused on the U.S. Initial Jobless Claims data on May 14, 2026, for broader sentiment cues, while specifically watching for management updates regarding the execution of the new obesity drug strategy and its impact on future margins.